Catalyst Pharmaceuticals Inc (CN2 F) stock market data APIs
€17.9947
0.02(0.1%)
as of November 7, 2025
Try our APIs with
free plan!
Catalyst Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Prev. Close
17.9947
Open
18.0116
High
18.392
Low
18.0775
52 wk Range
16.15-24
Market Cap
2 250 M
P/E Ratio
13.4179
Shares Outstanding
123 M
Revenue
578 M
Beta
0.688
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Catalyst Pharmaceuticals Inc data using free add-ons & libraries
Get Catalyst Pharmaceuticals Inc Fundamental Data
Catalyst Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 578 M
- EBITDA: 297 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: 0.54
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Catalyst Pharmaceuticals Inc News
New
Compared to Estimates, Catalyst (CPRX) Q3 Earnings: A Look at Key Metrics
Catalyst Pharmaceutical (CPRX) reported $148.39 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 15.3%. EPS of $0.68 for the same period compares to $...
Catalyst: Q3 Earnings Snapshot
CORAL GABLES, Fla. (AP) — CORAL GABLES, Fla. (AP) — Catalyst Pharmaceutical Partners Inc. (CPRX) on Wednesday reported third-quarter profit of $52.8 million. On a per-share basis, the Coral Gable...
Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Catalyst Pharmaceuticals, Inc. Reported Q3 2025 Total Revenues of $148.4Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising...
Santhera Closes USD 13 Million Royalty Monetization Agreement
Santhera Pharmaceuticals Holding AG Pratteln, Switzerland, November 5, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the closing of a USD 13 million royalty monetization agreement, first an...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
